NADIA K GADDI

Allopathic & Osteopathic Physicians|Family Medicine HOUSTON, TX NPI 1336375013

General Payments — all program years on this page

$1,571.53

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 90
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $329.54 across 19 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $329.5419

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Novo Nordisk AS $87.895
Acerta Pharma LLC $83.025
Lilly USA, LLC $53.633
Boehringer Ingelheim Pharmaceuticals, Inc. $35.552
Amgen Inc. $34.162
GlaxoSmithKline, LLC. $18.421
ABBVIE INC. $16.871

By program year

Program yearAmountRecords
2018 $87.136
2019 $71.175
2020 $122.208
2021 $224.4914
2022 $252.2712
2023 $484.7326
2024 $329.5419

Records — PY2024 (19)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1096617524 Novo Nordisk Inc $16.00 06/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1096914182 Novo Nordisk Inc $13.69 05/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1096938063 Novo Nordisk Inc $21.40 08/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097532116 Novo Nordisk Inc $21.19 05/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097597589 Novo Nordisk Inc $15.61 10/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1103763524 ABBVIE INC. $16.87 08/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104217587 AstraZeneca Pharmaceuticals LP $15.99 04/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104387933 AstraZeneca Pharmaceuticals LP $13.89 10/03/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104481682 AstraZeneca Pharmaceuticals LP $14.89 06/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104649625 AstraZeneca Pharmaceuticals LP $22.04 12/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105442607 AstraZeneca Pharmaceuticals LP $16.21 09/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116472923 GlaxoSmithKline, LLC. $18.42 05/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117557861 Amgen Inc. $16.76 01/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117557863 Amgen Inc. $17.40 09/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117969336 Boehringer Ingelheim Pharmaceuticals, Inc. $16.41 02/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117969338 Boehringer Ingelheim Pharmaceuticals, Inc. $19.14 10/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135213679 Lilly USA, LLC $15.67 05/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135228707 Lilly USA, LLC $23.35 02/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135260003 Lilly USA, LLC $14.61 01/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.